NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer

Journal of Urology

Volumn 161, Issue 1, 1999, Pages 62-65

  Zippe, Craig ^a   Pandrangi, Lakshmi ^a   Agarwal, Ashok ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Bladder neoplasms; Carcinoma, transitional cell; Immunoassay; Nuclear matrix; Tumor markers, biological

Indexed keywords

TUMOR MARKER;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER RISK; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CYSTOSCOPY; CYTOPATHOLOGY; EARLY DIAGNOSIS; FEMALE; HEMATURIA; HUMAN; IMMUNOASSAY; INSURANCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SYMPTOMATOLOGY; TRANSITIONAL CELL CARCINOMA; TREATMENT INDICATION;

EID: 0032826253     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)62063-9     Document Type: Article

References (6)

1. Getzenberg, R. H., Konety, B. R., Oeler, T. A., Quigley, M. M., Hakam, A., Becich, M. J. and Bahnson, R. R.: Bladder cancer-associated nuclear matrix proteins. Cancer Res., 156:1690, 1996.
2. Carpinito, G. A., Stadler, W. M., Briggman, J. V., Chodak, G. W., Church, P. A., Lamm, D. L., Messing, E. M., Pasciak, R. M., Reservitz, G. B., Ross, R. N., Rusktalis, D. B., Sarosdy, M. F., Soloway, M. S., Theil, R. P., Vogelzang, N. and Hayden, C. L.: Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract. J. Urol., 156: 1280, 1996.
3. Akaza, H., Miyanaga, N., Tsukamoto, T., Ishikawa, S., Noguchi, R., Ishikawa, S., Kawabe, K., Kuboto, Y., Fujita, K., Obata, K., Hirao, Y., Kotake, T., Ohmori, H., Kumazawa, J., Koiso, K. and the NMP Study Group. Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer-screening for urothelial cancer in patients with microscopic hematuria. Jap. J. Cancer Chemother., 24: 837, 1997.
4. Soloway, M. S., Briggman, V., Carpinito, G. A., Chodak, G. W., Church, P. A., Lamm, D. L., Lange, P., Messing, E., Pasciak, R. M., Reservitz, G. B., Rusktalis, D. B., Sarosdy, M. F., Stadler, W. M., Theil, R. P. and Hayden, C. L.: Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J. Urol., 156: 363, 1996.
5. Miyanaga, N., Akaza, H., Ishikawa, S., Ohtani, M., Noguchi, R., Kawai, K., Koiso, K., Kobayashi, M., Koyama, A. and Takahashi, T.: Clinical evaluation of nuclear matrix protein 22 (NMP22) in urine as a novel marker for urothelial cancer. Eur. Urol., 31: 163, 1997.
6. Stampfer, D. S., Carpinito, G. A., Rodriguez-Villanueva, J., Willsey, L. W., Dinney, C. P., Grossman, H. B., Fritsche, H. A. and McDougal, W. S.: Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder. J. Urol., 159: 394, 1998.